Method for synthesizing molecular targeted drug nCoVshRNA·2ACE2

nCoVshRNA·2ACE2 addresses the issue of siRNA drug ineffectiveness against mutated coronaviruses by using bivalent ACE2 to deliver double-stranded shRNA, ensuring targeted interference and neutralization across various strains.

JP7595234B2Active Publication Date: 2024-12-06WOMEN S HOSPITAL ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022180750
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-08-01
Filing Date
2022-11-11
Publication Date
2024-12-06
Estimated Expiration
2042-11-11

AI Technical Summary

Technical Problem

Current siRNA drugs designed for coronaviruses are ineffective against mutated strains due to their reliance on single-strand siRNA and non-specific delivery, leading to reduced targeting accuracy and efficacy against a broad spectrum of virus strains.

Method used

Development of nCoVshRNA·2ACE2, which utilizes bivalent ACE2 polypeptides to bind to the viral receptor-binding domain (RBD) and deliver double-stranded shRNA to target cells, forming a 'shRNA-ACE2-RBD-virus' complex for targeted interference and neutralization.

Benefits of technology

nCoVshRNA·2ACE2 effectively targets and neutralizes a broad spectrum of coronavirus strains by specifically delivering shRNA to infected cells, enhancing stability and immune response, and reducing side effects of non-specific delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595234000029
    Figure 0007595234000029
  • Figure 0007595234000030
    Figure 0007595234000030
  • Figure 0007595234000031
    Figure 0007595234000031
Patent Text Reader

Abstract

To provide a method for synthesizing a molecular target drug nCoVshRNA 2ACE2.SOLUTION: A method for synthesizing a novel coronavirus molecular target drug nCoVshRNA 2ACE2 comprising: designing a common RNAi sequence siRNA of coronavirus and mutant strains thereof; synthesizing a small hairpin shRNA with loop attachment from two complementary siRNAs; synthesizing ACE2 or a transmembrane peptide ACE2 with a receptor binding domain RBD as a ligand; thereafter, ligating ACE2 to the sense strand / antisense strand of shRNA and synthesizing nCoVshRNA 2ACE2 consisting of an shRNA region and ACE2 region; therein, bivalent ACE2 plays a role in RBD neutralization and targeted delivery of shRNA, and ACE2-crosslinked "shRNA-ACE2-RBD-virus" complexes allows the shRNA to enter target cells following viral infection; not only can the side effects of non-specifically delivering shRNAs to uninfected cells be avoided, but a virus-neutralizing effect with anti-mutant virus strains and ACE2 can also be produced; furthermore, a compound is synthesized with bimolecular ACE2 and single molecule shRNA; the molecular weight and molecular structure of ACE2 is changed; and ACE2 was made more antigenic by the immune adjuvant action of shRNA, and anti-ACE2 produced by stimulating the body was made to have anti-viral effects again.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for synthesizing molecular targeted drug nCoVshRNA·2ACE2, which belongs to the field of biopharmaceuticals. [Background technology]

[0002] Human angiotensin-converting enzyme II (ACE2) is a type I transmembrane glycoprotein expressed in target cells. The full length of ACE2 is composed of 805 amino acids, of which amino acids 1-740 are located outside the cell membrane and are called extracellular ACE2, amino acids 741-763 are located in the transmembrane region and are called transmembrane ACE2, and amino acids 764-805 are located inside the cell and are called intracellular ACE2.

[0003] The structure of coronaviruses includes single-stranded positive-stranded nucleic acid (ssRNA), spike protein (S), membrane protein (M), envelope protein (E), and core-shell protein (N), where the N-terminus of the S protein is composed of a domain (S1-NTD) and a receptor-binding domain (S1-RBD).

[0004] Coronaviruses bind to ACE2 in target cells through their S1-RBD, undergo cell membrane fusion and endocytosis, and enter target cells through the ACE2 channel. This indicates that coronavirus RBD and target cell ACE2 are in a ligand-receptor relationship, and based on this, ACE2 polypeptide was designed as a targeting vector, and nCoVshRNA·2ACE2 was synthesized, which combines ACE2 polypeptide and RNAi sequence to deliver shRNA to ACE2. Due to the membrane-permeable peptide properties of ACE2, the siRNA drug in nCoVshRNA·2ACE2 can be delivered targetedly by ACE2, passing through the ACE2 channel of target cells and exerting a specific effect on virus-infected cells. ACE2 can bind to the virus RBD, so it can bind nCoVshRNA·2ACE2 and the virus to form a complex, and the siRNA drug in it can enter target cells along with the virus infection, playing a characteristic role on virus-infected cells. In addition, ACE2 can bind to the RBD, so nCoVshRNA·2ACE2 plays a role in closing the virus RBD and blocking the virus from infecting target cells.

[0005] RNA interference (RNAi) is a highly efficient sequence-specific gene silencing technology that brings about unimaginable future applications in the treatment of diseases, and many kinds of siRNA drugs have already been approved by the FDA and released. However, current siRNA drugs often use a single virus strain to design siRNA, single-stranded siRNA (antisense RNA) to prepare siRNA drugs, or non-targeting vectors to non-specifically deliver siRNA drugs. For coronaviruses that constantly mutate, siRNAs designed based on the above single virus strain will be off-target and ineffective due to coronavirus mutations, so it is necessary to compare among the mutated virus strains, extract siRNAs common to each virus strain that are not changed by favorable virus mutations, and use them to manufacture a wide range of siRNA drugs against mutated and mutating virus strains. When a non-targeting vector is used, the siRNA drug is delivered to cells that are not easily infected by coronaviruses due to not expressing ACE2, so it is necessary to design a targeting vector that can specifically deliver siRNA to target cells. More importantly, according to the RNAi mechanism reported by HreA et al., the efficiency of double-stranded RNA silent homologous mRNA produced by mixing sense RNA and antisense RNA is more than 100 times higher than that of single-stranded RNA (antisense RNA), indicating that accurate and effective RNAi technology should adopt double-stranded RNA (shRNA) containing both sense siRNA and antisense siRNA at the same time, rather than using single-stranded siRNA to produce drugs.

[0006] siRNA, a small interfering RNA, regulates gene expression so that siRNA delivered to cell plasma participates in RNAi and specifically degrades the complementary target signaling RNA (mRNA). Since siRNA itself has difficulty passing through the cell membrane and is easily degraded by RNA enzymes, it is often non-specifically transported and protected by methods such as wrapping it in conventional lipid nanoparticles. In this application, siRNA is synthesized into shRNA and ACE2 polypeptide is linked to the shRNA double-stranded end to achieve the purpose of specific transport and siRNA protection.

[0007] In the prevention and treatment of COVID-19, if nCoVsiRNA can be stably, specifically and sequentially delivered to target organs, tissues and cells with appropriate targeting vectors, localized in target cells, crossed the target cell membrane and released into the target cell slurry, and is effective against a broad spectrum of multiple mutant viral strains, it should be possible to develop better COVID-19 targeted gene therapy.

[0008] To solve this problem, the present invention designs and synthesizes a molecular targeted drug, nCoVshRNA·2ACE2. Summary of the Invention [Problem to be solved by the invention]

[0009] The objective of the present invention is to provide an nCoVshRNA·2ACE2 drug for targeted delivery of shRNA through ACE2, and its synthesis method and use, in which bivalent ACE2 binds to RBD to exert the effects of virus neutralization and targeted delivery of shRNA, and the shRNA delivered through ACE2 is indirectly bound to RBD to form a "shRNA-ACE2-RBD-virus" complex, which then allows the shRNA to be delivered through the complex for targeted delivery, which can enter target cells following viral infection and play the role of anti-mutant virus strain targeted across a broad spectrum. [Means for solving the problem]

[0010] The object of the present invention is achieved by the following technical aspects: Screening for anti-mutant virus strain targeting siRNA, synthesizing shRNA, and further attaching ACE2 polypeptide to the double-stranded end of the shRNA to synthesize the novel coronavirus molecular targeted drug nCoVshRNA·2ACE2.

[0011] Screening of anti-mutation virus strain targets: siRNAs are screened from common genes of various pathogenic coronaviruses and mutant virus strains, including consensus genes, super-consensus genes and / or consensus microsatellites, and the screened siRNAs are used as common targets of each mutant virus strain that do not change due to viral mutation, so as to have broad-spectrum anti-mutation virus strain effects.

[0012] Synthesis of anti-mutant virus strain targeting siRNA: The screened siRNA is synthesized into two complementary 21-25 nt oligonucleotide siRNAs, and a base sequence that functions as a spacer is synthesized.

[0013] Synthesis of shRNA: Two complementary oligonucleotide polypeptide siRNAs were synthesized, and a base sequence that functions as a spacer was further synthesized, and a hairpin-shaped shRNA duplex was synthesized so that the intermediate base sequence served as a spacer as a loop circle.

[0014] Preferred siRNA: The synthesized shRNA is constructed into an interference vector, and its mRNA expression, protein expression, and interference effect are detected. After siRNA design, synthesis, screening, iterative design, and verification, it is preferable that the siRNA has high silencing efficiency.

[0015] Synthesis of Preferred siRNAs and shRNAs: siRNAs, shRNAs synthesized as described above using preferred siRNA sequences contain chemical modifications to enhance stability and avoid detargeting.

[0016] Synthesis of ACE2 Polypeptides or Proteins: Synthetic ACE2 includes, but is not limited to, full-length ACE2, transmembrane ACE2 from amino acids 741-763, intracellular ACE2 from amino acids 764-805, extracellular ACE2 from amino acids 1-740, and codon-optimized ACE2 polypeptides or proteins.

[0017] Synthesis of nCoV-shRNA·2ACE2: The synthesized shRNA and ACE2 are linked by coupling methods such as disulfide bond, phosphodiester bond, dithiophospholipid bond, disulfide bond, oxime bond, amide bond or maleimide-mercapto bond, and synthesized into a compound; or ACE2-shRNA-ACE2 is directly synthesized from the amino acid level based on the nucleotide sequence of shRNA and the amino acid sequence of ACE2.

[0018] Purification of nCoVshRNA·2ACE2: Purify by high-performance liquid chromatography, reversed-phase high-performance liquid chromatography or ion-exchange chromatography.

[0019] Liposome modification of nCoVshRNA·2ACE2: Liposome-modified compounds were prepared by adsorption of positively charged liposomes with negatively charged shRNA; PEG-internalized liposome-modified compounds were prepared by mercaptoation of ACE2 amino groups to form maleimide-mercapto bonds between the mercapto groups and the maleic acid amide of liposomes; liposome-modified compounds were prepared by urethane bond formation between ACE2 amino groups and liposomes; liposome-modified compounds were prepared by liposome-modified siRNA linked to ACE2 or ACE2 fragments.

[0020] Validation of nCoVshRNA·2ACE2: Measure the antiviral effect of nCoVshRNA·2ACE2 against two or more different mutant virus strains at the in vitro cell level, and observe whether it has an anti-mutant virus strain effect across a broad spectrum of consensus genes; examine whether it has an effect of targeted delivery of shRNA in animals, and whether it produces ACE2-Ab upon stimulation of the host. Effect of the Invention

[0021] The beneficial effects of the present invention are: The present invention is designed to deliver siRNA drugs of shRNA targeting ACE2.

[0022] The distinguishing feature of the present invention compared with traditional siRNA drugs is that the present invention screens for siRNAs that target all coronaviruses and their mutant strains in common with each virus strain and do not change due to virus mutations, and endows these siRNAs with broad-spectrum anti-mutant virus strain effects.

[0023] The distinguishing feature between the present invention and traditional siRNA drugs is that traditional siRNA drugs use sense strand siRNA or antisense strand siRNA, that is, single strand siRNA, whereas the present invention uses sense strand siRNA synthesized into shRNA.According to RNAi mechanism, double strand RNA has more effective RNAi effect.Therefore, the design of the present invention is more accurate and conforms to RNAi mechanism.

[0024] The distinguishing feature of the present invention compared with traditional siRNA drugs is that, based on the characteristic that coronavirus infects by binding its receptor binding domain (RBD) to ACE2 expressed in susceptible host cells, the present invention has designed shRNA nCoVshRNA·2ACE2 to be targeted and delivered to ACE2, which is composed of a short hairpin-shaped shRNA domain and a double-stranded ACE2 domain. ACE2 plays the role of both delivering shRNA and binding coronavirus RBD. The "shRNA-ACE2-RBD-virus" complex formed by the binding of ACE2 to viral RBD can allow shRNA to enter target cells along with viral infection. This method of ACE2 delivering shRNA together with the virus avoids the side effects of non-specifically delivering shRNA to uninfected cells and allows shRNA to exert an anti-mutant virus strain effect on virus-infected cells.

[0025] Because siRNA / shRNA has negative charge, lipid solubility, poor permeability and stability, the permeability, stability and deliverability of siRNA / shRNA were optimized after synthesizing siRNA / shRNA and ACE2 into nCoVshRNA·2ACE2.

[0026] Furthermore, nCoVshRNA·2ACE2, synthesized with two ACE2 molecules and one shRNA molecule, plays a role in binding bivalent ACE2 to the viral RBD, neutralizing the virus and blocking the virus' infection of target cells.

[0027] In addition, nCoVshRNA·2ACE2 contains two ACE2 molecules and one shRNA molecule. shRNA is not only an antiviral but also an oligonucleotide-based immune adjuvant, so nCoVshRNA·2ACE2 has stronger antigenicity than single-molecule ACE2, and can stimulate the host to produce more efficient ACE2-Ab, which competes with the virus to bind to the ACE2 receptor of target cells, and further makes nCoVshRNA·2ACE2 (ACE2-Ab) have the effect of blocking viral infection.

[0028] In addition, liposome modification can allow shRNA to be slowly released in the body, prolong its efficacy, and be endocytosed into the cytoplasm, and can also act as an immune adjuvant to enhance the ACE2 immune effect in nCoVshRNA·2ACE2.

[0029] Furthermore, in vitro cell experiments demonstrated that the synthesized nCoVshRNA·2ACE2 was simultaneously effective against two different mutant virus strains, and demonstrated that it has an anti-mutant virus strain effect by targeting the consensus gene. In vivo animal experiments revealed that nCoVshRNA·2ACE2 has the effect of targeted delivery of RNAi in the animal body, and stimulated ACE2-Ab can suppress viral infection by closing the ACE2 receptor. [Brief description of the drawings]

[0030] [Figure 1] This is a technical roadmap for producing nCoVshRNA·2ACE2 according to the present invention. [Diagram 2] FIG. 1 is a schematic diagram showing the configuration of nCoVshRNA-2ACE2 of the present invention. [Diagram 3] FIG. 1 shows nCoVshRNA·2ACE2 of the present invention and examples of its application. [Figure 4] FIG. 1 is a schematic diagram of the ACE2-targeted delivery liposome-modified shRNA of the present invention. [Diagram 5] FIG. 1 is a schematic diagram of the ACE2-targeted delivery liposome-modified siRNA of the present invention.

[0031] In Figure 1, the process includes consensus gene screening, broad-spectrum anti-mutation virus strain targeted siRNA screening targeting the consensus gene, shRNA synthesis, and ACE2 synthesis, and finally nCoVshRNA·2ACE2 or ACE2shRNA is synthesized.

[0032] In Figure 2, 1 is a loop, 2 is an shRNA formed from two complementary sense and antisense strands, and 3 is two ACE2 polypeptides (proteins), which are linked to the sense and antisense strands of the shRNA, respectively. The shRNA is protected by ACE2 and is targeted and delivered to the viral receptor binding region RBD or ACE2 receptor channel by ACE2, after which the viral RBD passes through the ACE2 channel to specifically invade the cytoplasm of the target cell and degrade the viral target gene.

[0033] In Figure 3, 1 is a loop formed from the base sequence interval of the positive and negative strands of a small hairpin-shaped shRNA in a spacer. 2 is an shRNA formed by the complementary binding of two sense and antisense siRNAs, which target the coronavirus consensus gene as an interference target, and therefore have a broad-spectrum anti-mutation virus strain targeted gene therapy effect. 3 is ACE2 linked to the sense and antisense strands of the shRNA. 4 is a coronavirus. 5 is the coronavirus S protein receptor binding region RBD. 6 is the ACE2 receptor expressed by cells 7, and 8 is a cell that does not express ACE2. As shown in Figure 2, nCoVshRNA·2ACE2 is composed of loop 1, shRNA2 and ACE2 3. Coronavirus 4 infects cells 7 by specific binding of its receptor binding region RBD5 with the receptor ACE2 6, but coronavirus 4 does not infect cells 8 that do not express ACE2. ACE2 3 in nCoVshRNA·2ACE2 can bind to RBD5 of coronavirus 4 as well as ACE2 6 expressed by cells 7, so ACE2 3 can compete with ACE2 6 to bind RBD5, giving ACE2 3 the effect of inhibiting virus 4 from infecting cells 7. nCoVshRNA·2ACE2 plays the role of a vaccine in the later stage. ACE2 3 stimulates the host to produce anti-ACE2, and anti-ACE2 blocks ACE2 6, thereby producing the effect of inhibiting virus 4-infected cells 7. More importantly, the bridge of ACE2 3 forms a complex of "shRNA2-ACE2 3-RBD5-virus 4", allowing shRNA2 to enter cell 7 together with virus 4, and to target and interfere with the replication of virus 4 in cell 7, avoiding the toxic side effects caused by shRNA2 non-specifically entering cell 8 that is not infected with virus 4.

[0034] In Figure 4, 1 and 2 are respectively the loop and shRNA encapsulated in liposome 4, where the shRNA is formed by the complementary binding of two sense and antisense siRNA strands, and this siRNA targets and interferes with the coronavirus consensus gene; 3 is ACE2, which is exposed outside liposome 4 and plays a targeted delivery role; liposome 4 protects the shRNA and induces cellular endocytosis; and 5 is PEG, which enables the slow release and long-term circulation of siRNA, forming the ACE2-shRNA / Lip complex as shown in Figure 3.

[0035] In Figure 5, 1 is the siRNA encased in liposomes, 2 is the liposome layer, 3 is the PEG layer, and 4 is ACE2. Among them, siRNA plays the role of RNAi, liposome protects siRNA and induces cell endocytosis, PEG releases siRNA slowly and circulates efficiently, and ACE2 is the outermost layer and plays the role of targeted delivery of siRNA, forming an ACE2-siRNA / Lip complex as shown in Figure 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] Hereinafter, specific implementation methods of the present invention will be described in detail with reference to Figures 1, 2, 3, 4 and 5, but these illustrative descriptions do not limit the scope of protection limited to the claims of the present invention.

[0037] 1. Design of siRNA targeting super-consensus genes, consensus genes, or consensus microsatellites

[0038] 1. Design of super-consensus genes, consensus genes and consensus microsatellites

[0039] Technical line As shown in Figure 1, the whole genome (cDNA) sequence of the βcoronavirus genus (especially the new coronavirus and mutant virus strains) downloaded from the Genbank database (http: / / www.NCBI.nlm.nih.gov / genome / ) was searched for the longest consensus child sequence in the whole genome sequence, and the super-consensus gene or consensus gene was obtained. The whole genome downloaded from the Genbank database was compared with the sequence using Clustal W software to detect the similarity between different sequences, and the consensus microsatellite sequence was screened. The MEGA6.0 molecular evolutionary genetics analysis software was used to construct an amino acid species-based molecular evolutionary tree for the downloaded coronavirus amino acid sequence using the neighbor method (Neighbour-Joning, NJ), and the molecular mutation characteristics of the amino acid sequence were analyzed and optimized to infer the consensus gene sequence.

[0040] The following three super-consensus subsequences with the longest length and the next longest length were obtained, which are 22-30 bp in length, corresponding to the length of small RNAs, but these three subsequences are not found in higher organisms, especially humans.

[0041] SEQ ID NO.1(Subsequence 1) = ttaatacgacctctctgttggattttgaca (30bp); SEQ ID NO.2(Subsequence 2) = ggttcgcaacttcacaca gagt (22bp); SEQ ID NO.3(Subsequence 3) = caggcgtttgttggttgattaa (22bp).

[0042] The following three super-consensus subsequences with the longest length and the next longest length were obtained, which are 22-30 bp in length, corresponding to the length of small RNAs, but these three subsequences are not found in higher organisms, especially humans.

[0043] SEQ ID NO.4(Subsequence 1) = gttttacgacaacgatgttggtttaggaca (30bp); SEQ ID NO.5(Subsequence 2) = ggttcggttgttatatacgata (22bp); SEQ ID NO.6(Subsequence 3) = ggttcagagagtctcctattta (22bp).

[0044] The following five nucleotides yielded consensus microsatellites repeated multiple times: CTCTCT, AGAGAG, AAAAA, TATA, and CACA.

[0045] 2. Design of common target siRNAs for novel coronavirus mutant strains

[0046] The complete genome (cDNA) sequence of the βcoronavirus genus (especially the new coronavirus and mutant virus strains) downloaded from the Genbank database (http: / / www.NCBI.nlm.nih.gov / genome / ) was used to obtain multiple siRNA candidate sequences with a length of about 19 nt using Ambion's shRNA online design software (http: / / www.ambion.com / techlib / misc / siRNAtools.html) and DSIR software, and based on the RNA binding Tm value and specific comparison results, siRNAs are preferred. This allows the E, M, N, ORF1ab and S genes of the 18 currently discovered new coronavirus and its mutant virus strains to obtain the respective RNAi sequences (siRNAs) of each virus strain and the common target siRNA, which is the common RNAi sequence of each virus strain, among which the common siRNAs of each virus strain are shown in Table 1, and their sequences are labeled as SEQ ID NO.7-40. For example, the siRNAs with sequence numbers tagged (SEQ ID NOs. 41-58) in Table 2-5 are common target siRNAs for NC_04551.2, Delta strain, and Omicron strain, and the siRNAs without sequence numbers tagged are their respective RNAi sequences (siRNAs). Although the first-appearing NC_04551.2 strain has mutated into the Delta strain and the recent Omicron strain, each virus strain still possesses the common consensus sequence SEQ ID NOs. 41-58, which is unchanged and theoretically has a targeted interference effect, except for its own unique targeted interference sequence siRNA (the portion without sequence tagging).

[0047] Table 1. Common target siRNAs (SEQ ID NO. 7-40) screened from 18 novel coronavirus mutant strains TIFF0007595234000001.tif254169TIFF0007595234000002.tif244169

[0048] Table 2. siRNA candidate sequences of the E gene of novel coronavirus NC_04551.2, DELTA, and OMICRON strains TIFF0007595234000003.tif130169

[0049] Table 3. siRNA candidate sequences of the M gene of novel coronavirus NC_04551.2, DELTA, and OMICRON strains TIFF0007595234000004.tif186169

[0050] Table 4. siRNA candidate sequences of the N gene of novel coronavirus NC_04551.2, DELTA, and OMICRON strains TIFF0007595234000005.tif171169

[0051] Table 5. siRNA candidate sequences of the ORF 1 ab gene of the novel coronavirus NC_04551.2, DELTA, and OMICRON strains TIFF0007595234000006.tif152167

[0052] Table 6. siRNA candidate sequences of the S gene of novel coronavirus NC_04551.2, DELTA, and OMICRON strains TIFF0007595234000007.tif150170

[0053] 3. Screening of siRNAs targeting super-consensus genes, consensus genes, or consensus microsatellites

[0054] Using Clustal W software or other software, the above-mentioned designed super-consensus genes, consensus genes and consensus microsatellites are compared with the gene sequences of the normally screened siRNAs, the similarity between the different sequences is measured, and multiple siRNAs (designing siRNAs targeting the super-consensus genes, consensus genes or consensus microsatellites) that are also super-consensus genes, consensus genes or consensus microsatellites and RNAi target sites are also designed.

[0055] (1) siRNA targeting super-consensus genes and consensus microsatellites (S1 / S2): SEQ ID NO.1(Subsequence 1) = ttaatacgacctctctgttggattttgaca (30bp); SEQ ID NO.2(Subsequence 2) = ggttcgcaacttcacaca gagt (22bp);

[0056] (2) siRNA targeting consensus genes and consensus microsatellites (S3 / S4): SEQ ID NO.5(Subsequence 3) = ggttcggttgttatatacgata (22bp); SEQ ID NO.6(Subsequence 4) = ggttcagagagtctcctattta (22bp).

[0057] Through the above design, siRNAs for virus strains theoretically resistant to coronavirus mutations that interfere with super-consensus genes, consensus genes or consensus microsatellites were obtained and named siRNA 1 / 2 / 3 / 4.

[0058] 2. Verification of common target siRNA

[0059] 1. Synthesis of siRNA / shRNA

[0060] According to the RNAi mechanism, when siRNA effectively interferes with the mRNA expression of the S gene, an S protein-deficient virus that loses infectivity is formed. When siRNA effectively interferes with the mRNA expression of the N gene, viral packaging and replication are inhibited. When siRNA effectively interferes with the mRNA expression of the ORF 1 a or 1 b gene, it affects the synthesis of viral RNA polymerase (RdRp) or protein processing enzyme (3 CLpro). Meanwhile, the M and E genes are viral membrane genes, and the inhibitory effect of their defects on the virus may not be clear. Therefore, the present invention uses siRNA (SEQ ID NO.16-18, SEQ ID NO.49-51) of the targeted N gene, siRNA (SEQ ID NO.20-22, SEQ ID NO.52-54) of the targeted ORF 1 ab gene, and siRNA (SEQ ID NO.30-32, SEQ ID NO.56-58) of the targeted S gene, as well as SEQ ID NO.1-2, SEQ ID NO.5-6 to synthesize. In addition, we designed an shRNA template that can express a hairpin structure at the polyclonal enzyme cut site for the pSilencer 4.1.CMV.neo interference vector, and each template is composed of two mostly complementary 55 bp single-stranded DNAs, which can form a DNA duplex with sticky ends at the BamH I and Hind III enzyme cut sites after annealing and complementation, and are used to link with the linearized pSilencer 4.1.CMV.neo. Then, we ask the company to synthesize the siRNA based on the designed siRNA and its shRNA template.

[0061] 2. Construction of shRNA expression vector

[0062] The above synthesized shRNAs were identified by ligating with the linearized interference vector pSilencer 4.1.CMV.neo, respectively, to construct shRNA expression plasmids, and transformed into DH5a to obtain the respective shRNA expression vectors.

[0063] 3. Identification of the effect of shRNA expression (interference) vector

[0064] Based on the synthesized siRNA / shRNA and its constructed expression plasmid, the corresponding target gene was selected for synthesis or PCR amplification, then a fluorescently labeled vector was constructed, and the shRNA expression plasmid was co-transfected with type II alveolar epithelial cells (AEC 2S) or 293 T cells, respectively, for identification. The usual method of PCR amplification is as follows: Primer design: In the design, initiation codes are added to the 5' ends of the downstream primer and the upstream primer, and homologous arms are added to the 5' ends of the primers for homologous recombination with the vector in order to clone the amplified product into pEGFP-N1.

[0065] Amplification of target gene: According to the gene amplification reaction system and reaction conditions provided by the Shanghai Biotechnology Kit, gene amplification, product recovery and purification are carried out to obtain the amplified product.

[0066] Linearization of pEGFP-N1: DH5a strain containing pEGFP-N1 plasmid was recovered, the plasmid was extracted based on the reagent kit, the concentration was measured, and then enzyme digestion was performed. The linearized carrier was identified and recovered by 0.8% agarose gel electrophoresis.

[0067] Ligation of the amplified target gene with the fluorescent labeling vector (pEGFP-N 1): Genscript After ligation, the products can be stored at -20°C or used for transformation immediately.

[0068] Identification of the effect of shRNA interference vector: The interference vector (pSilencer-shRNA) and the fluorescent labeling vector (pEGFP-N / S / OAF 1 ab) were co-transfected into 293T cells, respectively, with the mass ratio of interference vector to labeling vector being 1:2. At the same time, a control was set up, and the intracellular GFP protein fusion expression was observed 48 h after transfection, and the interference effect was evaluated based on the fluorescence intensity.

[0069] Flow cytometry: To quantitatively analyze the interference effect of different interference vectors, measure using flow cytometry and analyze the percentage of fluorescent protein-expressing cells in the total cell number.

[0070] Westernbolt analysis: (i) Cell collection and digestion: digest cells with RIPA. (ii) SDS-PAGE protein electrophoresis: prepare SDS-PAGE gel, add samples to equal volume of 2xSDS buffer, boil water bath for 5 min, ice bath for 2 min, 12000 xg, 10 min. (iii) Western blot examination: transfer membrane, closing, primary antibody binding, washing, secondary antibody binding and color development, and observe the results.

[0071] Detection of mRNA by RT-PCR: Relative quantitative real-time RT-PCR was used to detect the relative expression level of the target gene in transfected cells, and the copy numbers of the target gene and the internal reference gene B-actin were converted from the CT value based on the standard curve. The relative expression level of viral gene mRNA (target gene copy number / B-actin copy number) was corrected with the internal reference gene B-actin to quantitatively evaluate the interference effect.

[0072] 4. Obtain siRNA / shRNA with high silencing efficiency

[0073] Through the above-mentioned design, synthesis, screening, iterative design, resynthesis and cell-level verification, siRNAs with high silencing efficiency were obtained, whose sequences were SEQ ID NO.1 (named shRNA 1, hereinafter the same), SEQ ID NO.2 (shRNA 2), SEQ ID NO.5 (shRNA3), and SEQ ID NO.16 (shRNA 4), SEQ ID NO.49 (shRNA 5) of the target N gene, SEQ ID NO.21 (shRNA 6), SEQ ID NO.52 (shRNA 7) of the target ORF 1 ab gene, and SEQ ID NO.30 (shRNA 8) of the target S gene, with silencing efficiencies of 78%, 76%, 88%, 89%, 89%, 84%, 91% and 90%, respectively.

[0074] 3. Synthesis of shRNA

[0075] Based on the above screened common targets (SEQ ID NO.1-58), SEQ ID NO.5 (shRNA3), SEQ ID NO.49 (shRNA 5) and SEQ ID NO.30 (shRNA 8) with short target gene sequences were selected and sent to a biological company for synthesis. For each shRNA, two complementary 19-25 nt oligonucleotide polypeptide siRNAs were synthesized, and a 9 nt base sequence acting as a spacer was synthesized. The synthesized siRNA (drug) and base sequence were then linked to a small hairpin-shaped shRNA double strand, so as to act as a spacer from the intermediate base sequence as a loop ring. Each single strand of the synthesized shRNA double strand can link to an ACE2 polypeptide or protein, respectively.

[0076] For example, using SEQ ID NO.1(shRNA1), SEQ ID NO.2(shRNA2), and SEQ ID NO.5(shRNA3), 5'-ttaatacgacctctctgttggattttgacattcaagagatgtcaaatccaacagagaggtcgtattaa-3'(shRNA1)(SEQ ID NO: 77), 5'-ggttcgcaacttcacacagagtttcaagagaactctgtgtgaagttgcgaacc-3'(shRNA2)(SEQ ID NO: 78) and 5'-ggtt cggt tgtta tatac gata ttcaagaga tatc gtata taaca accg aacc-3'(shRNA3)(SEQ ID NO: 79) is synthesized, in which "TTCAAGA" is a loop, the right side is a complementary sense strand, the right side is an antisense strand, and the 3' and / or 5' are linked to ACE2 protein or its polypeptide. Similarly, other siRNAs with high silencing efficiency are preferred, and shRNAs are synthesized respectively.

[0077] 4. Design and synthesis of targeted delivery vector ACE2

[0078] 1. Amino acid sequence of ACE2

[0079] The human ACE2 gene sequence information was searched for in the GeneBank database (http: / / www.ncbi.nlm.gov / genbank), and it was found that ACE2 is composed of 805 amino acids, of which the amino acid sequence at positions 1-740 (SEQ ID NO.59) is located outside the cell membrane, the amino acid sequence at positions 741-763 (SEQ ID NO.60) is located in the transmembrane domain, and the amino acid sequence at positions 764-805 (SEQ ID NO.61) is located inside the cell. Of the 20 amino acids that make up the ACE2 protein, leucine accounts for 9.4%, cysteine ​​and histidine account for 1.0% and 2.0%, respectively, and there are negatively charged amino acid residues (asparagine + glutamic acid) and positively charged amino acid residues (arginine + lysine), etc. SARS-CoV and SARS-CoV 2 interact with the extracellular catalytic structural region of ACE2 through the viral receptor binding region, and this interaction can trigger cell endocytosis, membrane fusion, and thus SARS-CoV enters cells containing highly expressed ACE2 or ACE2 receptors.

[0080] 2. ACE2 receptor function

[0081] ACE2 is a lipophilic type I transmembrane glycoprotein with an amino-terminal catalytic domain and a carboxyl-terminal domain, of which the N-terminus is outside the cell membrane and the C-terminus is inside the cell membrane, and is divided into an N-terminal signal peptide region, a carboxypolypeptidase activation region and a transmembrane region. When coronavirus Spike protein contacts the tip of subdomain I of the ACE2 catalytic domain (which does not affect subdomain II and peptide enzyme activity), the ectodomain of ACE2 is degraded and the transmembrane domain is internalized, which is thought to be involved in the transport of the virus-receptor complex from the cell membrane to the cytoplasm for further virus-host cell fusion.

[0082] 3. Design of the ACE2

[0083] According to the amino acid sequence of ACE2 and the receptor function of ACE2, there is an ACE2 receptor channel in the cell wall and cell membrane of ACE2-expressing cells, and full-length ACE2, transmembrane ACE2, intracellular ACE2 and extracellular ACE2 all belong to transmembrane polypeptides, which have the function of targeted delivery of siRNA, and the N-terminus of extracellular ACE2 has the function of binding to coronavirus RBD and neutralizing viruses. Full-length ACE2, extracellular ACE2 with amino acids 1-740, transmembrane ACE2 with amino acids 741-763 or intracellular ACE2 with amino acids 764-805, or ACE2 polypeptide with optimized amino acid sequence can be designed and synthesized as a targeted delivery vector for siRNA.

[0084] 4. Synthesis of the present ACE2

[0085] Two amino acids are dehydrated and condensed to form a peptide bond, and multiple amino acid residues are bound by peptide bonds to form a polypeptide. You can commission a company to use a polypeptide synthesizer to automatically synthesize polypeptides. The basic method is to add amino acids one by one according to the sequence of the synthetic polypeptide, gradually extend the peptide chain from the C-terminus to the N-terminus, condense each amino acid residue in the form of one-end protection and the other-end activation, and then remove the temporary protecting group on the amino group after each peptide chain extension cycle, completing the condensation of the entire amino acid sequence of the target polypeptide. The reaction principle of solid-phase synthetic polypeptides, which is currently commonly used, is to continuously add the required amino acids in the order of C-terminus-carboxyl end to N-terminus-amino end according to the known sequence in a sealed explosion-proof glass reactor, carry out the synthesis reaction, and finally obtain the polypeptide. The process includes: (i) deprotection: remove the protecting group of the amino group with an alkaline solvent; (ii) activation and crosslinking: activate the carboxyl group of the next amino acid, crosslink the activated monomer carboxyl group with the free amino group to form a peptide bond, and repeat the two-step reaction cycle until the polypeptide synthesis is completed.

[0086] 5. Synthesis of nCoVshRNA·2ACE2 by ACE2 and shRNA

[0087] 1. Design of nCoVshRNA 2ACE2

[0088] Taking the synthesis of shRNA and extracellular, transmembrane or intracellular ACE2 as an example, one end of the sense strand / antisense strand of the synthesized siRNA / shRNA is linked to a loop (5'-TTCAAGAGA-3') and the other end is linked to ACE2 (C-terminus), respectively, to form a structure of "ACE2-siRNA sense strand-loop ring-siRNA antisense strand-ACE2", which is expressed as "2ACE2-shRNA", among which the two complementary sense strands / antisense strands form a double strand, but the two ACE2 polypeptides do not form a double strand, as shown in Figure 2, it is an shRNA with two ACE2 polypeptides, two siRNA sense strands / antisense strands and a hairpin-shaped linker with a loop ring. The viral RBD binds to the N-terminus of ACE2 infected cells through the C-terminus, and the binding of ACE2 polypeptide with siRNA can increase the permeability, stability and interference effect of siRNA, so that, as shown in Figure 3, ACE2 in this design not only neutralizes the virus and blocks viral infection, but also delivers siRNA / shRNA to the viral receptor binding region RBD to form a complex of "shRNA-ACE2-RBD-virus", and the shRNA can be delivered by the virus, and the shRNA can enter the target cells along with the viral infection and exert the effect of target interference.

[0089] 2. Synthesis of ACE2-shRNA-ACE2 (2ACE2-shRNA)

[0090] The company is commissioned to synthesize polypeptide-oligonucleotide conjugates (POCs) based on the sequences of extracellular ACE2, SEQ ID NO. 5 (shRNA 3), transmembrane ACE2, SEQ ID NO. 49 (shRNA 5), and SEQ ID NO. 30 (shRNA 8) according to the design (Figure 2) using a conventional synthesis method for polypeptides and oligonucleotides, in which the above-synthesized polypeptide (ACE2) and oligonucleotide (shRNA / siRNA) are linked together in the form of a carboxyhydrazone bond, an oxime bond, an amide bond, a sulfide bond, a thioether bond, a disulfide bond, a phosphonyl bond, a hydrazone bond, a ureido bond, a phosphodiester bond, a dithiophospholipid bond, a maleimide-mercapto bond, or the like, and the sense strand (5' end, 3' end) or the antisense strand (3' end) of the polypeptide and the oligonucleotide are crosslinked by a non-covalent bond or a covalent bond with a strong covalent bond, a loose ionic bond, a hydrophobic bond, or a carboxyhydrazone bond with a spacer arm. At present, the most common synthetic POCs method is the bond-crosslinking-liquid-phase fragment synthesis method, which has been widely applied to the synthesis of various POCs. Its main steps are: synthesizing a polypeptide and an oligonucleotide on a solid-phase substrate, respectively, then simultaneously separating the two synthetic products from the solid-phase substrate, and coupling the separated polypeptide and oligonucleotide through reactive groups in solution. Synthetic POCs mainly include: (i) maleimide-mercapto coupling: modifying a maleimide on a polypeptide or oligonucleotide and a mercapto group on another monomer, and adding the two monomers to the same solution to react to obtain POCs; (ii) sulfide bond or thioether bond coupling: modifying the 5' or 3' position of an oligonucleotide with a thiol group, and then coupling it with a polypeptide whose C-terminus has been modified with a bromine acetyl group at pH 7.0 buffer solution, disulfide bond coupling can be directly oxidized by two sulfhydryl groups, or the sulfhydryl groups can be activated by activating agents such as bipyridine dithioether before coupling with an oligomer containing another sulfhydryl group. Generally, siRNA and polypeptide can be coupled by disulfide bond. (iii) Oxime bond coupling: Aldehyde group and amino group react with each other to produce oxime. The reaction conditions are mild, the reaction efficiency is high, and it can directly produce the coupling product of double-stranded DNA and a specific polypeptide. At the same time, two polypeptides can be simultaneously linked to the 5' and 3' ends of nucleic acid through oxime bond via bifunctional oligonucleotide and polypeptide or sugar. This method does not require various protection processes and can be completed in one step, and is called "peptide-oligonucleotide-peptide". (iv) Amide bond coupling: The product is obtained by directly reacting an oligomer containing an activated carboxylic acid or thioester with another polymer modified with an amino group; (v) Hydrazone bond coupling: The hydrazine group is first introduced into the polypeptide, and then a citrate buffer with a pH between 3-5 is added to react with an oligonucleotide modified with an acetaldehyde group to obtain POCs linked by hydrazone bonds, which are expressed as "2ACE2-shRNA3", "2ACE2-shRNA 5" and "2ACE2-shRNA 8", respectively.

[0091] 3. Purification of ACE2-shRNA-ACE2

[0092] Chromatography is one of the most common methods to purify and analyze the coupling of polypeptides and oligonucleotides. Different chromatographic methods should be selected for separation according to the complexity of the coupling, the main methods are high-efficiency liquid chromatography (HPLC), reverse high-efficiency liquid chromatography (RP-HPLC), ion exchange chromatography (IEC, usually anion exchange chromatography), or two or several of them in series, specifically, follow the operating instructions to extract 2ACE2-shRNA3, 2ACE2-shRNA5, 2ACE2-shRNA8.

[0093] 4. Synthesis of other compounds for targeted delivery of shRNA at ACE2

[0094] Similarly, shRNA (SEQ ID NO.1-58) and intracellular ACE2 or codon-optimized ACE2 polypeptide can be linked to a compound, including but not limited to "transmembrane ACE2-shRNA-transmembrane ACE2" and "intracellular ACE2-shRNA-intracellular ACE2", or shRNA / siRNA can be inserted into the middle of ACE2 polypeptide to synthesize "transmembrane ACE2-shRNA-extracellular ACE2" and "intracellular ACE2-shRNA-extracellular ACE2", and compounds using ACE2 or its optimized polypeptide as a targeting delivery vector can be similarly designed, including but not limited to "ACE2-siRNA, extracellular ACE2-siRNA, transmembrane ACE2-siRNA, intracellular ACE2-siRNA".

[0095] 6. Modification of compounds with liposomes

[0096] Liposome (Lip) modification includes the adsorption of positively charged liposomes with negatively charged shRNA, the mercaptoation of amino groups in the ACE2 polypeptide to form mercapto-maleimide bonds between the mercapto groups and liposomes, or the formation of urethane bonds between the ACE2 amino groups and liposomes (Figures 4-5).

[0097] Example 1: Preparation of liposome-modified compounds with liposomal DOTAP / Chol

[0098] (1) Preparation of lipid solution

[0099] DOTAP (MW=698.5): 10 mg / ml. Accurately weigh out 100 mg of DOTAP [N-1-(2,3-di-oleoyloxy)propyl)-N,N,N,N-trimethylammoniumethyl sulfate] powder and add it to a 10 ml volumetric bottle, then add chloroform solution up to the graduation line.

[0100] Chol (MW=386): 5 mg / ml. 50 mg of cholesterol powder was accurately weighed and added to a 10 ml volumetric bottle, and chloroform solution was added up to the graduation line.

[0101] m-PEG2000-DPE (MW=2778): 10 mg / ml. 10 mg of m-PEG2000-DPE (methoxypolyethylene glycol-distearoyl phosphatidyi-ethanolamine) powder was weighed out, 1 ml of DEPC water was added, and the mixture was vortexed and then sonicated for 1 minute to completely dissolve.

[0102] Mal-PEG2000-DSPE (MW=2941.6): 10 mg / ml. 1 ml of DEPC water was added to 10 mg of Mal-PEG2000-DPE (Methoxy-polyethylene glycol-distearoyl phosphatidyi-ethanolamine) powder, vortexed, and then sonicated for 1 minute to completely dissolve.

[0103] (2) Preparation of liposomal DOTAP / Chol (membrane hydration method)

[0104] Lipid-film method was used to prepare liposome DOTAP / Chol, the lipid concentration was 10 mM, and the main steps were as follows: According to the amount of 1ml liposome DOTAP / Chol produced, chloroform solutions of two kinds of lipids, DOTAP and Chol, were taken, and added to a 500ml Erlenmeyer flask in a ratio of DOTAP:Chol=1:1 (M:M), and 3-4ml chloroform solution was added. Vacuum rotary evaporation was performed at 37℃ for 45-60min to obtain a uniform lipid film, and a trace amount of chloroform was blown out with high purity nitrogen gas, 1ml of DEPC water was added and vibrated, the lipid film was washed from the bottle wall, and a lipid suspension was obtained. After sufficient hydration, it was ultrasonicated for 1min, and extruded through 400nm, 200nm, 80nm, and 50nm polycarbonate membranes in sequence, 10-20 times each, to obtain liposome DOTAP / Chol.

[0105] (3) Mercaptoylation of ACE2 and 2ACE2-shRNA

[0106] 2-IT (Traut's reagent) is a commonly used reagent for protein mercaptoylation, which can perform mercaptoylation at the N-amino group of ACE2 protein. The steps are as follows: 2ACE2-shRNA and 2-IT (Traut's reagent, 2-iminotiolane-HCl) are taken, mixed homogeneously (the molar ratio of 2-IT to 2ACE2-shRNA is 200:1), and reacted at room temperature for 2 h. Excess 2-IT is removed by dialysis, and a sufficient amount of dialysis solution (1×PBS, 5 mM EDTA, pH=7.4) is used each time, stored at 4℃, dialyzed every other night, magnetically stirred, and the dialysis solution is exchanged for 6-8 hours. The protein concentration and degree of mercaptoylation were measured using the BCA method and the Ellman method, respectively.

[0107] (4) Preparation of liposome-modified compounds using liposome DOTAP / Chol

[0108] (A) Negatively charged siRNA / shRNA is used to adsorb and prepare positively charged liposomes.

[0109] (i) 120 μl of DOTAP / Chol liposomes (10 mM) was taken, 20 μl of 2ACE2-shRNA (approximately 2 μg / μl, 40 μg) was added, 11 μl of DEPC water was added, and the mixture was left to stand at room temperature for 10 min to obtain the liposome-modified complex 2ACE2-shRNA / ch1.

[0110] (ii) 90 μl of siRNA (24 μg, 20 mM) or 90 μl of shRNA (24 μg, 10 mM) was taken, 57.6 μl of DEPC water was added, and the mixture was left to stand at room temperature for 10 min. Then, 600 μl of DOTAP / Chol liposomes (50 mM) was added to obtain siRNA / ch1 and shRNA / ch1.

[0111] (iii) The liposome-modified complex 2ACE2-shRNA / ch1 prepared in (i) and the liposome-modified complex siRNA / ch or shRNA / ch prepared in (ii) were mixed in equal amounts to obtain the corresponding mixed liposome-modified complex.

[0112] (B) Preparation by crosslinking reaction between mercapto groups in ACE2 and maleimide in PEG

[0113] To increase the circulation time and target specificity of the liposomes, (A) the various liposome-modified complexes prepared were further PEGylated and modified with ACE2 to obtain PEGylated liposome-modified complexes with RBD as a ligand.

[0114] 9.53 μl (6.36 μl and 12.7 μl are used as controls) of 10 mg / ml MAL-DSPE-PEG was taken and inserted into the liposome-modified complex 2ACE2-shRNA / ch1, siRNA / ch1 or shRNA / ch1 prepared in (A) above (each of them was mixed), incubated in a water bath at 50° C. for 10 min, and allowed to stand at room temperature for 10 min. After that, about 200 μg of the above sulfhydryl-modified ACE2 or 2ACE2-shRNA / ch1 was added, and the sulfhydryl group on the sulfhydryl amino acid in ACE2 was crosslinked with the maleimide in MAL-DSPE-PEG to produce ACE2-modified and PEGylated (the PEGylated PEG concentrations were 5 molar 1% PEG, 7.5 molar 1% PEG, and 10 molar PEG, respectively). The complexes were prepared by electrostatically adsorbing siRNA, shRNA, and / or 2ACE2-shRNA on the lipid body DOTAP / Chol, then wrapping the outer layer with MAL-DSPE-PEG, and finally linking ACE2 or 2ACE2-shRNA with MAL-DSPE-PE-PEG to prepare liposome (ch)-modified complexes, which included ACE2-siRNA / ch1, ACE2-shRNA / ch1, ACE2-(2ACE2-shRNA / ch1), (2ACE2-shRNA)-siRNA / ch1, (2ACE2-shRNA)-shRNA / ch1, (2ACE2-shRNA)-(2ACE2-shRNA / ch1), which are abbreviated as ACE2-siRNA / ch1, ACE2-shRNA / ch1, 3ACE2-shRNA / ch1, 2ACE2-shRNA / siRNA / ch1, 2ACE2-2shRNA / ch1, and 4ACE2-2shRNA / ch1, respectively. As shown in Figure 3, ACE2 plays a role in targeted delivery of siRNA / shRNA, while liposomes and PEG play the roles of protecting siRNA / shRNA, slowly releasing siRNA / shRNA, transfecting siRNA / shRNA into cells, or acting as immune adjuvants.

[0115] Example 2: Preparation of liposome-modified compounds using liposomal

[0116] At pH>8, the reaction of the amino group of ACE2 with pNP-PEG-DPPE (PEG-PE) forms a stable urethane bond conjugate, which quantitatively inserts into the outer membrane of liposomes to prepare a liposome-modified compound. In this example, a liposome-modified compound was prepared using ACE2 fragments and siRNA to target and deliver siRNA (ACE2-siRNA) at ACE2.

[0117] (1) Synthesis of ACE2

[0118] ACE2 or a fragment thereof was synthesized using the ACE2 synthesis method described above.

[0119] (2) Synthesis of pNP-PEG-DPPE

[0120] 10 ml of 20 mg / mL chloroform solution of DPPE (dipalmitoylethanolamine) was taken and placed in a 50 mL round-bottom flask, 0.65 mL of triethylamine (TEA) was dropped, and about 4.0 g of chloroform solution of (pNP)2-PEG3400 (polyethylene glycol 3400 di-p-nitrophenyl carbonate) with a concentration of 200 mg / mL was added to the above mixture, nitrogen gas was blown in, the flask was sealed, and the mixture was kept away from light and magnetically stirred at room temperature overnight. The solvent was evaporated to dryness under reduced pressure, the residual chloroform was removed in vacuum, and 100 mL of 0.01 mol / L HCl aqueous solution was added and ultrasonicated to form a transparent micellar solution. The eluent was 0.01 mol / L HCl aqueous solution, and the mixture was separated through CL-4 B Sepharose to remove unreacted (pNP)2-PEG3400 and released pNP. The eluent containing pNP-PEG-DPPE micelles was collected and lyophilized, and the pNP-PEG-DPPE was qualitatively and quantitatively analyzed by TLC, HPLC, MS, and NMR.

[0121] (3) Synthesis of ACE2-PEG-DPPE: 100 mg of pNP-PEG-DPPE was dissolved in 10 mL chloroform, placed in a 50 mL flask, and the chloroform was removed under reduced pressure on a rotary evaporator to form a lipid film. The residual chloroform was removed under vacuum, and 25 mg of ACE2 was dissolved in 4 mL of 0.01 mol / L HCl, placed in a flask with an inner wall-coated lipid film, incubated at room temperature for 30 minutes, and gently shaken to disperse the lipid film. 20 mL of 10 mum / L (pH 9.0) Tris buffer was added to the suspension, mixed, nitrogen-protected, and incubated overnight at 4°C. The sample was placed in a dialysis bag with a molecular mass of 5 kD, dialyzed in 10 mmol / L (pH 7.4) Tris buffer for about 4 hours, and further dialyzed against deionized water at 4°C for 24 hours. The solution in the bag was removed, freeze-dried, and stored in a refrigerator at -20°C.

[0122] (4) Synthesis of ACE2-siRNA / liposomal: ePC (egg yolk phospholipid), Ch (cholesterol), PEG2000-DPE (distearate-ethanolamine polyethylene glycol 2000) and DOTAP (dioleyltrimethylaminepropane) chloroform solutions were mixed in a molar ratio (60:34:3.0:3.0). If it is necessary to label the lipid membrane, Rho-PE at a mass molar ratio of 0.1% of the total lipids was added to the above mixture, and the chloroform was removed under reduced pressure to form a lipid membrane. A certain amount of siRNA was dissolved in DEPC-treated ultrapure water, and the amount of siRNA used must completely neutralize the positive charge on DOTAP. The above phospholipid membrane was hydrated for 30 minutes using an siRNA-containing aqueous solution in a water bath at 50 °C to form a liposome encasing siRNA. Using a manual extrusion device (Avanti Polar Lipids), the initially formed liposomes were passed through 0.4 μm and 0.1 μm polycarbonate track-etched membranes (Whatman) 10 times to prepare liposomes with uniform particle size. An appropriate amount of ACE2-PEG-DPPE was dissolved in methanol, placed in a flask, and nitrogen gas was blown in to form a membrane, and the prepared liposome suspension was added and incubated in a 37°C water bath for 2 hours to allow ACE2-PEG-DPPE to be orientated and inserted onto the outer membrane of the liposome, and the molar ratio of ACE2 to the total lipid was adjusted to 0.5%-1.0% (suitably adjustable). Using dynamic laser scattering, freeze fracture-transmission electron microscopy and nucleic acid electrophoresis examination, the liposome (ch / lip) complex ACE2-shRNA / siRNA / lip shown in Figures 3-4 was prepared.

[0123] nCoVshRNA·2ACE2 was synthesized with shRNA / siRNA from ACE2 or its polypeptide and further modified with liposomes.

[0124] Seventh, validation of compound (nCoVshRNA·2ACE2)

[0125] 1. In vitro verification of broad-spectrum antiviral effects

[0126] (1) Preparation of virus solution

[0127] The virus strain was added to DMEM culture medium (10% FBS) in which Vero E 6 cells were grown to 30% confluence, and cultured at 36°C in a 5% CO2 culture box for 5-7 days. When cytopathic effect (CPE) appeared, the virus was isolated and mixed with the culture medium to prepare a virus solution at 103-105 TCID50 / ml. Based on this, in order to prove the presence or absence of the broad-spectrum antiviral effect of the shRNA / siRNA of the present invention targeting the consensus gene, and to verify whether nCoVshRNA·2ACE2 is effective against two or more mutant viruses containing the same consensus gene at the same time, virus solutions of two types of mutant virus strains of the novel coronavirus, B.1.617.1 and B.1.617.2, were prepared.

[0128] (2) The compound (nCoVshRNA·2ACE2) and the virus were simultaneously cultured.

[0129] Test and control groups were set up to test the anti-B.1.617.1 and anti-B.1.617.2 effects of the compounds. 8 wells of inoculated plates, 2 x 105 Vero-E6 cells per well, 2 mL of DMEM culture medium (10% FBS) were cultured in a 36℃, 5% CO2 culture box until 30% confluence. The culture medium was replaced and the test compound and virus solution of B.1.617.1 and B.1.617.2 strains were added at the same time.

[0130] Reagents: 2ACE2-shRNA3 group (0.1nmol 2ACE2-shiRNA3 + 0.6ml virus solution), 2ACE2-shARNA3 / ch1 group (0.1nmol 2ACE2-shRNA3 / ch1 + 0.6ml virus solution), 4ACE2-2SHRNA3 / ch1 group (0.1nmol 4ACE2-2SHRNA3 / ch1 + 0.6mL virus solution), ACE2-siRNA3 / lip group (0.1nmol ACE2-siRNA3 / lip + 0.6ml virus solution); Control groups: naked shRNA3 group (0.1nmol naked shRNA3 + 0.6ml virus solution), naked siRNA3 group (0.1nmol naked siRNA3 + 0.6ml virus solution), ACE2 control group (0.1nmol ACE2 + 0.6ml virus solution), positive control group (0.6ml virus solution), negative control group (0.6ml DMEM culture medium) (Tables 1-6). Experiments for 2ACE2-shRNA5 and 2ACE2-shRNA8 were performed similarly (Tables 1a-6a).

[0131] After that, after 1 hour, 24 hours, and 72 hours of culture, the supernatant was taken from each group and diluted 1:4, 1:12, 1:36, 1:108, 1:324, 1:972, 1:2916, and 1:8748 times for RT-PCR testing.

[0132] (3) Detection of viral RNA in each group by fluorescent real-time RT-PCR

[0133] Viral nucleic acid extraction and nucleic acid (ORF1ab / N) detection were performed according to the kit instructions.

[0134] (4) Viral RNA detection results

[0135] (i) Test results for the B.1.617.1 strain

[0136] As shown in Table 1, after 1 hour of cell culture in each group, the viral RNA test result of the negative control group was negative, the RNA test result titer of the positive control group was 1:36, and the RNA test result titers of the other groups were all 1:12.

[0137] As shown in Table 2, after 24 hours of cell culture in each group, the viral RNA detection results of the negative control group were still negative, the viral RNA detection results of each control group were 1:324-1:2916, and the viral RNA detection results of the experimental groups were all 1:108, which was obviously lower than that of the positive control group and the ACE2 control group (p<0.01).

[0138] As shown in Table 3, after 72 hours of cell culture in each group, the viral RNA test results of the negative control group were still negative, the titers of the RNA test results of each control group were >1:2916, the titers of the RNA test results of the control group were >1:2916-1:8748, and the titers of the RNA test results of the control group were 1:324-1:972, which were significantly lower than those of the control group (p<0.01).

[0139] As can be seen from Tables 1-3, the experimental group showed obvious anti-B.1.617.1 strain effect, indicating that shRNA or siRNA linked to ACE2 can be delivered into target cells to perform RNA interference, while shRNA or siRNA not linked to ACE2 cannot enter target cells and cannot play the role of RNA interference outside the cells. The results of Tables 1a-3a were almost consistent with Tables 1-3.

[0140] Table 1. Viral RNA RT-PCR test results for culture medium incubated with compound (shRNA3) and B.1.617.1 strain for 1 hour TIFF0007595234000008.tif83163

[0141] Table 1a. Viral RNA RT-PCR test results for culture fluids incubated simultaneously with 2ACE2-shRNA5 / 8 and B.1.617.1 strain for 1 hour TIFF0007595234000009.tif81163

[0142] Table 2. Viral RNA RT-PCR test results for culture medium cultured simultaneously for 24 hours with compound (shRNA3) and B.1.617.1 strain TIFF0007595234000010.tif83162

[0143] Table 2a. Viral RNA RT-PCR test results for culture fluids of ACE2-shRNA5 / 8 and B.1.617.1 strains cultured simultaneously for 24 hours TIFF0007595234000011.tif84162

[0144] Table 3. Viral RNA RT-PCR test results for culture fluids cultured simultaneously with compound (shRNA3) and B.1.617.1 strain for 72 hours TIFF0007595234000012.tif83163

[0145] Table 3a. Viral RNA RT-PCR results for culture fluids of 2ACE2-shRNA 5 / 8 and B.1.617.1 strains cultured simultaneously for 72 hours TIFF0007595234000013.tif83162

[0146] (ii) Test results for the B.1.617.2 strain

[0147] As shown in Table 4, after 1 hour of cell culture in each group, the viral RNA test results of the negative control group were negative, the RNA test results of the positive control group and the ACE2 control group were all 1:36, and the RNA test results of the other groups were all 1:12. As shown in Table 5, after 24 hours of cell culture in each group, the viral RNA test results of the negative control group were still negative, the titers of the RNA test results of each control group were 1:324-1:972, and the titers of the RNA test results of the four experimental groups were 1:36-1:108, which were obviously lower than the control group (p<0.01). As shown in Table 6, after 72 hours of cell culture in each group, the viral RNA test results of the negative control group were still negative, the RNA test results of each control group were 1:2916-1:8748, and the RNA test results of the four experimental groups were 1:324 for two groups and 1:972 for the other two groups, which had obvious differences compared with the control group (p<0.01). Tables 4-6 show that the experimental group showed obvious anti-B.1.617.2 strain effect, shRNA or siRNA linked to ACE2 can be delivered into target cells to perform RNA interference, and shRNA or siRNA not linked to RBD cannot enter target cells and cannot play the role of RNA interference. The results of Tables 4a-6a were almost consistent with the results of Tables 4-6. Tables 1-6 and Tables 1a-6 show that the experimental group (nCoVshRNA·2ACE2) has anti-B.1.617.1 and B.1.617.2 effects at the same time, and the experimental group nCoVshRNA·2ACE2, which targets the consensus gene for interference, has anti-mutant virus strain effect over a broad spectrum.

[0148] Table 4. Viral RNA RT-PCR test results for culture medium incubated with compound (shRNA3) and B.1.617.2 strain for 1 hour TIFF0007595234000014.tif82162

[0149] Table 4a. Viral RNA RT-PCR test results for culture fluids incubated simultaneously for 1 hour with 2ACE2-shRNA5 / 8 and B.1.617.2 strains TIFF0007595234000015.tif84162

[0150] Table 5. Viral RNA RT-PCR test results for culture medium cultured simultaneously for 24 hours with compound (shRNA3) and B.1.617.2 strain TIFF0007595234000016.tif81161

[0151] Table 5a. Viral RNA RT-PCR test results for culture fluids of 2ACE2-shRNA5 / 8 and B.1.617.2 strains cultured simultaneously for 24 hours TIFF0007595234000017.tif84162

[0152] Table 6. Viral RNA RT-PCR test results for culture fluids cultured simultaneously with compound (shRNA3) and B.1.617.2 strain for 72 hours TIFF0007595234000018.tif81161

[0153] Table 6a. Results of viral RNA RT-PCR test of culture fluids cultured simultaneously for 72 hours with 2ACE2-shRNA5 / 8 and B.1.617.2 strains TIFF0007595234000019.tif83163

[0154] 2. In vivo validation of ACE2 targeted delivery function

[0155] (1) Grouping and inoculation of animals

[0156] Animal grouping: SPF female BALB / c mice aged 6-8 weeks and weighing approximately 40 grams were selected and randomly divided into the following groups: 2ACE2-shRNA3 (shRNA5 / 8) group (inoculated with 2ACE2-shRNA3 + B.1.617.2), 2ACE2-shRNA3 / ch1 group (inoculated with 2ACE2-shRNA3 / ch1 + B.1.617.2), 4ACE2-2shRNA3 / ch1 group (inoculated with 4ACE2-2shRNA3 / ch1 + B.1.617.2), ACE2-siRNA3 / lip group (inoculated with ACE2-siRNA3 / lip + B.1.617.2), shRNA3 group (inoculated with shRNA3 + B.1.617.2), positive control group (inoculated with B.1.617.2 + saline) and negative control group (inoculated with saline only), with 20 mice in each group.

[0157] Animal inoculation: 40μl of virus solution of B.1.617.2 strain with a titer of 105 / ml TCID50 was inoculated by nasal spray, and 40μl of saline was inoculated by nasal spray for the negative control group. The mice were anesthetized by intraperitoneal injection of 5% aldehyde chloride hydrate solution, and 0.1nmol of 2ACE2-shRNA, 2ACE2-shRNA / ch1, 4ACE2-2shRNA / ch1, ACE2-siRNA / lip and shRNA were slowly injected into the mouse trachea. On the 7th day after infection, 10 mice from each group were killed and tested for virus. In addition, 10 mice from each group were used to observe antibodies.

[0158] (2) Detect the virus as a percentage of the median infectious dose (TCID50) of cells

[0159] The lung tissues of the mice sacrificed on the 7th day after infection were used to prepare a 10% homogenized pulp. 100 pl of each supernatant was collected after centrifugation and serially diluted 10-fold, and inoculated into a 96-well plate with VeroE6 monolayer growth. 30 μl was inoculated into each well, and 4 wells were inoculated for each dilution. The homogenized slurry was gently shaken and adsorbed at 37°C for 1 hour, washed with Hank's solution, culture medium was added, and cultured in a 37°C CO2 culture box. The cytopathic effect (CPE) was observed, and the percentage of VeroE6 median infectious dose (TCID50) of each group was calculated. The higher the percentage, the higher the virus content (Table 7-13).

[0160] Table 7. Percentage of VeroE6 median infectious dose by homogenized lung tissue pulp of mice in the 2ACE2-shRNA3 group TIFF0007595234000020.tif54152

[0161] Table 8. Percentage of VeroE6 median infectious dose in homogenized lung tissue pulp of mice in the ACE2-shRNA3 / ch1 group TIFF0007595234000021.tif55150

[0162] Table 9. Percentage of VeroE6 median infection dose by homogenized lung tissue pulp of mice in the 4ACE2-2shRNA3 / ch1 group TIFF0007595234000022.tif54150

[0163] Table 10. Percentage of VeroE6 median infection dose by homogenized lung tissue pulp of mice in the ACE2-siRNA3 / lip group TIFF0007595234000023.tif54152

[0164] Table 11. Percentage of VeroE6 median infection dose in homogenized lung tissue pulp from shRNA3 mice TIFF0007595234000024.tif53150

[0165] Table 12. Percentage of median infectious dose of VeroE6 in homogenized lung tissue pulp of mice from the positive control group TIFF0007595234000025.tif54151

[0166] Table 13. Percentage of median infectious dose of VeroE6 in homogenized lung tissue pulp of negative control mice TIFF0007595234000026.tif54151

[0167] (3) Effect of targeted delivery of ACE2

[0168] From Tables 7-13, the percentage of median infection dose of VeroE6 by homogenous pulp of mouse lung in each group (101 wells) was 35.0% in the 2ACE2-shRNA3 group, 27.5% in the 2ACE2-shRNA3 / ch1 group, 32.5% in the 4ACE2-2shRNA3 / ch1 group, 30.0% in the ACE2-siRNA3 / lip group, 95.0% in the shRNA3 group, 95.0% in the positive control group, and 5.0% in the negative control group, respectively. RNAi mainly occurred within the cell plasma, and shRNA3 in the shRNA3 group was difficult to cross the cell membrane, so there was little RNAi effect, and the results were consistent with the positive control; on the other hand, shRNA3 in the 2ACE2-shRNA3 group, 2ACE2-shRNA3 / ch1 group, 4ACE2-2shRNA3 / ch1 group and ACE2-siRNA3 / lip group was targeted and delivered to the cytoplasm of target cells by ACE2, so the RNAi effect was high, and the percentage of VeroE6 median infectious dose was significantly different from that of the positive control group (p<0.05).

[0169] According to the above TCID50 test method, the TCID50 test was performed on 2ACE2-shRNA8 and 2ACE2-shRNA 8 / ch1. The TCID50 of the 2ACE2-shRNA8 group, 2ACE2-shRNA8 / ch1 group, shRNA8 group, positive control group and negative control group were 25%, 17.5%, 82.5%, 95% and 7.5%, respectively, and the TCID50 of the test groups was obviously lower than that of the positive control group.

[0170] 3. Detection and functional verification of ACE2-Ab

[0171] (1) Samples and detection methods

[0172] Venous blood was collected from 10 mice from each of the above separate groups on the 2nd, 4th, and 6th weeks of the study, and serum was separated. The serum from each group was mixed with that from the same week and stored at -20°C. ACE2-Ab was measured by double antigen sandwich method, specifically following the procedure of the kit.

[0173] (2) Detection results

[0174] From Table 14, the ACE2-Ab of the lung tissue homogenous pulp of mice in each experimental group (containing ACE2) was significantly higher than that of the lung tissue homogenous pulp of mice in the control group (not containing ACE2) (p<0.05), indicating that ACE2 in the experimental group could stimulate the mice to produce ACE2-Ab, and the content of the produced ACE2-Ab was related to the ACE2 molecular composition and liposome modification.

[0175] Table 14. ACE2-Ab test results (ng / L) of homogenized lung tissue pulp from mice in each test group (with ACE2) TIFF0007595234000027.tif50165

[0176] (3) Functional verification of ACE2-Ab

[0177] The 2ACE2-shRNA group, 2ACE2-shRNA / ch1 group, 4ACE2-2shRNA / ch1 group and ACE2-siRNA / lip group were the test groups (all containing ACE2-Ab), and the shRNA group was the control group (containing virus but not ACE2-Ab). The sera from each group at 2, 4 and 6 weeks after the ACE2-Ab test were mixed, and the mixed sera from each group were diluted 2-fold, and then inoculated into a VeroE6 monolayer growth 96-well plate with 30 μl each. At the same time, each test group was inoculated with 30 μl of undiluted mixed serum from the shRNA group, and the negative control group was inoculated with only 30 μl of saline. The mixture was gently rocked and mixed, adsorbed at 37°C for 1 hour, washed with Hank's solution, added with culture medium, and cultured at 37°C in a CO2 culture box. Cytopathic effect (CPE) was observed within 1 week, and "+" represented normal cell growth, as shown in Table 15.

[0178] Table 15. Antiviral infection results by neutralization of ACE2 on VeroE6 cells by ACE2-Ab (+ / CPE) TIFF0007595234000028.tif74164

[0179] As can be seen from Table 15, the negative control group was not inoculated with the virus, so no CPE appeared in each well VeroE6; the positive control group was inoculated with the virus without ACE2-Ab neutralization (shRNA3 group did not dilute the mixed serum), so each well VeroE6 produced CPE; the shRNA3 group had no ACE2-Ab neutralization, so CPE did not appear in VeroE6 only after the autologous serum containing the virus was diluted 1:128 times; on the other hand, each test group was inoculated with the virus like the positive control group, but had ACE2-Ab neutralization, so CPE appeared in VeroE6 when the serum, i.e., ACE2-Ab content, was diluted 1:64 or more. This shows that ACE2-Ab can neutralize the viral receptor ACE2 on the surface of VeroE6 cells, thereby having an antiviral effect.

[0180] The shRNA of the present invention acts as an anti-mutation virus strain, and ACE2 plays a role in targeting and delivering shRNA, bivalent binding RBD, competitively inhibiting infection by the viral RBD, protecting shRNA3, and stimulating the host to produce ACE2-Ab, which can close ACE2. In addition, multi-molecule ACE2 and adjuvant shRNA3 and liposomes can both promote the production and action of ACE2-Ab.

Claims

1. A method for synthesizing a molecular targeted drug that blocks infection of cells by the novel coronavirus (SARS-CoV-2), comprising: A method for synthesizing a molecular targeted drug, comprising synthesizing double-stranded RNA containing a sense strand siRNA and an antisense strand siRNA of an RNAi sequence targeting the novel coronavirus gene, and linking human angiotensin-converting enzyme II to one end of each of the sense strand siRNA and the antisense strand siRNA.

2. The method for synthesizing a molecular targeted drug according to claim 1, characterized in that, in synthesizing the double-stranded RNA, the other ends of the sense strand siRNA and the antisense strand siRNA are linked using a predetermined base, thereby forming the double-stranded RNA into a hairpin shape with the predetermined base in the middle.

3. The method for synthesizing a molecular targeted drug according to claim 1 or 2, characterized in that the sense strand siRNA and the antisense strand siRNA are encapsulated in a liposome, and the human angiotensin-converting enzyme II linked to one end of each of the sense strand siRNA and the antisense strand siRNA is exposed outside the liposome.

4. The method for synthesizing a molecular targeted drug according to claim 1 or 2, characterized in that the human angiotensin-converting enzyme II is at least any one of extracellular ACE2 at positions 1-740 in the full-length amino acid sequence of human angiotensin-converting enzyme II, transmembrane ACE2 at positions 741-763 in the amino acid sequence, and intracellular ACE2 at positions 764-805 in the amino acid sequence.

5. The method for synthesizing a molecular targeted drug described in claim 1 or 2, characterized in that the new coronavirus includes B.1.617.1 and B.1.617.

2.

6. 3. The method for synthesizing a molecular targeted drug according to claim 1, wherein the sense strand siRNA and the antisense strand siRNA are each 21-25 nt siRNA.

7. The method for synthesizing a molecular targeted drug according to claim 1 or 2, characterized in that the sense strand siRNA or the antisense strand siRNA consists of any of the base sequences shown in SEQ ID NO. 1-58.

8. The method for synthesizing a molecular targeted drug according to claim 7, characterized in that the sense strand siRNA or the antisense strand siRNA consists of any of the base sequences shown in SEQ ID NO. 1, 2, 5, 16, 21, 30, 49, or 52.

Citation Information

Patent Citations

  • Polypeptide-nucleic acid conjugates and their use

    JP2011505846A

  • Antisense antiviral compounds and methods for treating influenza virus infections

    JP2013510584A

  • COMPOSITION AND METHODS OF RNAi PROPHYLACTICS AND THERAPEUTICS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY INFECTION CAUSED BY 2019 NOVEL CORONAVIRUS (2019-nCoV)

    WO2021151096A2